Project Grant R44NS143576
- This federal Project Grant award of $431,676 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is funding research to investigate the role of the glucocorticoid receptor (GR) and its interaction with the cytochrome P450 (CYP) and P-glycoprotein (PGP) pathways in regulating anti-seizure medication bioavailability across the blood-brain barrier in drug-resistant epilepsy with...
- This federal Project Grant award of $414,305 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant will fund research to identify key molecules and pathways underlying the process of epileptogenesis, with the goal of developing therapies to modify disease progression. The research leverages a novel algorithm called MAGIC combined with a large...
- This $579,294 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand the cell type-specific epigenetic mechanisms, particularly involving microRNAs, that regulate brain function and contribute to neurological disorders like epilepsy. The research aims to reveal the specific cell types and target mRNAs...
- This $357,191 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to mechanistically link acute seizures with chronic alterations in cholinergic networks in a mouse model of Dravet syndrome. The primary objective is to delineate seizure-associated pathology in the cholinergic pedunculopontine nucleus (PPN) to identify targets for...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,830,581 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Johns Hopkins University. The grant supports in-depth characterization of the mechanism of action of a new macrocycle molecule called RAPIREON, which selectively activates the nuclease activity of the IRE1 protein in the unfolded protein response (UPR) pathway....
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $323,001.00 to Axonis Therapeutics, Inc. to develop an oral KCC2 potentiator compound, AXN-027, as a novel anti-epileptic drug for mesial temporal lobe epilepsy (MTLE). The key products and services to be delivered include using a mouse model of MTLE to investigate the anti-seizure...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $222,160 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of California, San Diego (UCSD). The grant will support Dr. Alena Stasenko's research to develop risk and resilience models of cognitive aging in epilepsy and novel, tech-based interventions to improve brain health. The project aims to leverage digital assessment to determine the...
- This federal Project Grant award of $657,958 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research into the cellular and network mechanisms of epilepsy and neuromodulation. The research team from Trustees of Boston University will use cutting-edge cellular membrane voltage imaging, optogenetics, and local field potential recordings in cortical...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $512,438 to Vanderbilt University Medical Center (VUMC) on September 16, 2025 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant, titled "Scaling Up Task-Shifted Epilepsy Care (SHIFT)," aims to integrate task-shifted epilepsy care and malnutrition care in five communities with populations over 100,000 people. The project...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $18,593,020 Cooperative Agreement on January 15, 2025 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the Rector & Visitors of the University of Virginia. The award will fund a Phase III randomized, double-blind clinical trial to evaluate whether adding ketamine (1 or 3 mg/kg) to the standard levetiracetam therapy is more effective than levetiracetam alone...
The National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, awarded a $1,499,869 Project Grant to Respirerx Pharmaceuticals Inc. on September 23, 2025. The grant supports the development of a novel GABA receptor potentiator, KRM-II-81, for the treatment of epilepsy. The key objectives of the project include developing the chemistry, manufacturing, and control (CMC) processes for KRM-II-81 production at the lab scale and scaling up the manufacturing, as well as evaluating the in vitro absorption, distribution, metabolism, and excretion (ADME) properties and in vivo pharmacokinetics of the compound. This work aims to advance the preclinical development of KRM-II-81 as a potential new therapy for epilepsy, which is a common and burdensome neurological condition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 9/23/25 |